Participants
The sample size was set a priori, using the main outcome of increased Achilles tendon stiffness. The required sample size was calculated using G*Power 3.137 with α = 0.05 and an anticipated moderate effect (f = 0.25) of the…
The sample size was set a priori, using the main outcome of increased Achilles tendon stiffness. The required sample size was calculated using G*Power 3.137 with α = 0.05 and an anticipated moderate effect (f = 0.25) of the…
Principal Component Analysis (PCA) revealed distinct differences in gene expression between asthma and control groups in the GSE179156 dataset (Fig. 2a). A total of 758 DEGs were identified using the Limma…
Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for malaria to date, showed a 26% reduction in new…
Amyotrophic lateral sclerosis (ALS) – which you may know as the disease that affected Stephen Hawking – is a fatal neurodegenerative disease that causes progressive muscle weakness. A research team at Tohoku University and Keio…
Amyotrophic lateral sclerosis (ALS) – which you may know as the disease that affected Stephen Hawking – is a fatal neurodegenerative disease that causes progressive muscle weakness. A research team at Tohoku University and Keio…
Autophagy is essentially the ‘rubbish collection’ of our cells. If there are problems in this process, which is so important for our health, diseases such as Parkinson’s can result. In their latest study, leading cell biologists at…
A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types. The new advance,…
A potential target for experimental drugs that block PRMT5 – a naturally occurring enzyme some tumors rely more on for survival – has been identified by researchers with the Fralin Biomedical Research Institute’s Cancer Research…
VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl…
A new study led by Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, shows how a key molecule regulates the generation of new blood cells, a process…